There is a molecule that has been present in human experience since before recorded history. It grows from the earth in hundreds of species of mushrooms across every inhabited continent. It has been depicted in cave paintings estimated to be tens of thousands of years old. It was central to the religious and healing practices of pre-Columbian Mesoamerican civilizations — the Mazatec, the Aztec, the Maya — who called it teonanácatl: the flesh of the gods. And in the past two decades, after fifty years of prohibition that froze scientific investigation entirely, it has returned to the research laboratory — and what researchers are finding there is shaking the foundations of psychiatry, neuroscience, and our understanding of consciousness itself.
That molecule is psilocybin. And its story — chemical, neurological, historical, and deeply human — is one of the most extraordinary stories of our time.
What Psilocybin Is
Psilocybin is a naturally occurring psychedelic compound found in approximately 200 species of mushrooms in the genus Psilocybe and related genera. It is classified chemically as a tryptamine — a class of compounds closely related in structure to serotonin, the neurotransmitter that regulates mood, perception, appetite, sleep, and many other physiological processes. Psilocybin itself is a prodrug — it is pharmacologically inactive until the body converts it, within minutes of ingestion, to psilocin, which is the compound that actually produces psychedelic effects by binding to serotonin receptors throughout the brain.
The primary receptor psilocin acts on is the 5-HT2A serotonin receptor, which is particularly concentrated in the prefrontal cortex — the brain region responsible for complex thinking, self-reflection, decision-making, and the integration of emotional and cognitive information. The activation of 5-HT2A receptors by psilocin produces a cascade of neurological effects that are still being fully characterized, but that include dramatically altered patterns of brain connectivity, suppression of the default mode network (the brain’s self-referential processing system), and the emergence of brain activity patterns not seen in ordinary waking consciousness.
The Ancient Relationship
The relationship between human beings and psilocybin mushrooms is ancient beyond our ability to fully trace. The Tassili n’Ajjer cave paintings in Algeria, estimated to be between 7,000 and 9,000 years old, depict figures that many researchers interpret as mushroom-human composites — beings with mushrooms growing from their bodies, surrounded by geometric patterns consistent with descriptions of psychedelic visual phenomena. Rock art from the Saharan region, dating to similar periods, shows analogous imagery.
In Mesoamerica, the evidence is clearest. Mushroom stones — carved stone sculptures depicting mushrooms in anthropomorphic forms — have been found throughout Guatemala and southern Mexico dating to at least 1000 BCE. The Aztec manuscripts describe the ceremonial use of teonanácatl — psilocybin mushrooms — in religious ceremonies, healing rituals, and divination practices supervised by trained healers called curanderas. When Spanish colonizers arrived in the 16th century, they encountered these practices and moved systematically to suppress them, driving the tradition underground. For four centuries, the knowledge survived primarily among the Mazatec people of Oaxaca, who maintained their mushroom ceremony traditions in relative secrecy.
In 1955, R. Gordon Wasson — a banker and amateur mycologist — became one of the first Westerners to participate in a Mazatec mushroom ceremony, guided by the curandera María Sabina. His account, published in Life magazine in 1957, introduced psilocybin mushrooms to the Western world and sparked a wave of scientific and cultural interest that culminated in the isolation and synthesis of psilocybin by Swiss chemist Albert Hofmann in 1958 and the subsequent explosion of psychedelic research in the 1960s before prohibition ended it.
What Happens in the Brain
Modern neuroimaging has given researchers the ability to watch what psilocybin does to the living brain — and what they have found is both technically fascinating and philosophically profound.
The default mode network goes quiet. The default mode network (DMN) is a set of brain regions that is most active when the brain is at rest and least active during focused tasks. It is the network of self-referential thought — of mind-wandering, rumination, autobiographical memory, and the construction and maintenance of the sense of self. It is also the network most implicated in depression, anxiety, addiction, and the rigid, repetitive thought patterns that characterize these conditions. Psilocybin dramatically suppresses activity in the DMN — producing the experience of ego dissolution that psychedelic users describe as the boundary between self and world temporarily dissolving — and simultaneously allows previously unconnected brain regions to communicate with each other in patterns not seen in ordinary consciousness.
Neuroplasticity increases dramatically. Psilocybin promotes neuroplasticity — the brain’s capacity to form new connections and reorganize existing ones — through multiple mechanisms, including the promotion of dendritic spine growth and the upregulation of brain-derived neurotrophic factor (BDNF). This means that psilocybin literally makes the brain more capable of changing — of forming new patterns of thought and perception that were previously inaccessible. The rigidity of depression, addiction, and anxiety — the stuck quality of these conditions — may be at least partly a neuroplasticity deficit. Psilocybin addresses that deficit directly at the biological level.
Entropy increases. Researchers including Robin Carhart-Harris have measured something called neural entropy — the complexity and unpredictability of brain activity patterns — under psilocybin and found that it increases significantly. More entropic brain activity corresponds to a wider repertoire of possible brain states — more cognitive and perceptual flexibility, more openness to new perspectives, less entrenchment in habitual patterns. Depression, trauma, and addiction are characterized by low neural entropy — the brain stuck in rigid, low-diversity activity patterns. Psilocybin appears to reset this toward higher entropy, creating the conditions for genuine psychological flexibility.
The Research Renaissance: What Clinical Trials Are Finding
Beginning in the early 2000s, a new generation of researchers at Johns Hopkins, NYU, Imperial College London, and other institutions began carefully designed clinical trials of psilocybin-assisted therapy. The results have been striking enough to generate genuine excitement in a field — psychiatry — that has seen relatively little innovation in treatment approaches for decades.
Depression. Multiple randomized controlled trials have found that one or two psilocybin-assisted therapy sessions produce rapid, significant, and durable reductions in depression symptoms in patients with treatment-resistant depression — patients who have not responded to multiple conventional antidepressant treatments. In a landmark 2021 study published in the New England Journal of Medicine, psilocybin-assisted therapy produced outcomes comparable to a leading SSRI antidepressant, but with faster onset and — crucially — without the emotional blunting that many patients find intolerable with conventional antidepressants. Patients in psilocybin trials frequently describe not just symptom reduction but a fundamental shift in their relationship to their thoughts and emotions — a new perspective that persists long after the acute psychedelic experience has ended.
Addiction. Early studies of psilocybin-assisted therapy for tobacco addiction found abstinence rates at six-month follow-up of over 80% — dramatically higher than any conventional cessation treatment. Studies of psilocybin for alcohol use disorder have found significant reductions in drinking and significant increases in abstinence. The mechanism may involve the disruption of the rigid self-narratives and habitual patterns that maintain addictive behavior — psilocybin’s suppression of the default mode network creating a window of psychological openness in which new patterns can take root.
End-of-life anxiety. Some of the most moving research on psilocybin involves its effects on anxiety in people facing terminal illness. In studies at NYU and Johns Hopkins, a single psilocybin session produced dramatic and lasting reductions in death anxiety, depression, and existential distress in patients with cancer and other life-threatening diagnoses — with effects persisting at six-month follow-up in the majority of participants. Many participants described the experience as one of the most meaningful of their lives — producing a shift in their relationship to death that allowed them to live their remaining time with greater presence, less fear, and deeper connection to the people they loved.
PTSD and trauma. Research on psilocybin for PTSD is in earlier stages but showing significant promise, consistent with the broader pattern of psilocybin’s ability to create windows of neuroplasticity and psychological openness in which traumatic memories can be reprocessed rather than avoided or re-experienced.
The Mystical Experience: The Most Mysterious Finding
Here is where the science becomes genuinely strange — and genuinely profound. Researchers studying psilocybin-assisted therapy have found, consistently and across multiple studies, that the magnitude of therapeutic benefit correlates with the intensity of what participants describe as a mystical experience — an experience characterized by feelings of unity, sacredness, deeply felt positive emotion, a sense of noetic quality (the conviction that one has accessed genuine truth), and transcendence of time and space.
The more completely a participant experiences what William James described as the hallmarks of mystical experience, the better their therapeutic outcomes. This is a remarkable finding for several reasons. It suggests that the therapeutic mechanism of psilocybin is not simply pharmacological — not simply the chemical action of psilocin on serotonin receptors — but involves the phenomenological content of the experience itself. The feeling of unity, of encountering something larger than the self, of accessing a reality that feels more real than ordinary experience — these experiential qualities appear to be therapeutically active.
This is difficult to account for within the purely materialist framework that Western medicine operates from. If a drug works because a molecule binds to a receptor, the content of the experience the drug produces should be irrelevant to the outcome. But for psilocybin, it is not irrelevant. The experience — its quality, its depth, its mystical character — is the mechanism. The molecule is the door. What walks through the door, and what it finds there, is what heals.
The Mystery at the Heart of the Research
The deepest mystery psilocybin research opens is the oldest mystery in philosophy: the nature of consciousness itself. The psychedelic experience produces states of consciousness so far outside ordinary experience — states of unity, of encountering what users describe as fundamental reality, of accessing dimensions of being not available in ordinary waking life — that they challenge the assumption that consciousness is simply the product of brain activity.
The philosopher and psychedelic researcher Aldous Huxley proposed that the brain functions not as a generator of consciousness but as a reducing valve — filtering out the vast majority of conscious experience to leave only the narrow band relevant to biological survival. In this model, psychedelics do not add something to consciousness. They remove the filter. What floods in when the filter is reduced — the sense of universal unity, the encounter with what feels like the fundamental ground of reality, the conviction of having touched something more real than ordinary experience — may not be hallucination. It may be the experience of consciousness as it actually is, without the filter that ordinarily reduces it to the serviceable but impoverished slice available to ordinary waking awareness.
This is not a fringe idea. It is taken seriously by some of the most rigorous philosophers and neuroscientists working on the hard problem of consciousness today. And the psilocybin research — particularly the consistent therapeutic role of the mystical experience — is generating data that makes it harder, not easier, to dismiss.
The Current Landscape
As of 2026, psilocybin-assisted therapy has been decriminalized or is under active regulatory review in a growing number of jurisdictions. Oregon became the first US state to legalize supervised psilocybin services in 2020, with a licensed service framework that opened in 2023. Colorado followed with a similar framework. Several cities have decriminalized personal psilocybin use. Australia approved psilocybin-assisted therapy for treatment-resistant depression in 2023. The FDA has granted psilocybin Breakthrough Therapy designation for both depression and addiction, signaling recognition of its exceptional therapeutic promise and expediting the review process for potential future approval.
The conversation is changing. The research is compelling. And the molecule that has been growing in the earth and changing human consciousness since before the beginning of recorded history is finding its way back into legitimate medical and scientific discourse — carrying with it implications not just for psychiatry but for our deepest understanding of what it means to be a conscious being in a universe that may be far more alive, far more connected, and far more extraordinary than ordinary waking consciousness typically allows us to perceive.
Positive thoughts create positive outcomes. And psilocybin research suggests that the most positive thoughts of all — of unity, of love, of connection to something larger than the self — may not be merely thoughts. They may be the most accurate perception of reality available to a human mind.
Explore the Mushroom Collection
High Phase celebrates the extraordinary world of fungi — from the mycelial networks beneath our feet to the molecules that have been expanding human consciousness since before recorded history.